Recent clinical and pathophysiological advances in non-functioning pituitary adenomas

Hormone Research

Volumn 71, Issue SUPPL. 2, 2009, Pages 123-130

  Korbonits, Márta ^a   Carlsen, Eivind ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Pituitary adenoma; Silent pituitary adenoma; Somatostatin analogues; Temozolomide

Indexed keywords

ANGIOPEPTIN; HORMONE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OCTREOTIDE; PASIREOTIDE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; ZAC 1 PROTEIN; ZINC FINGER PROTEIN;

ACTH SECRETING ADENOMA; CANCER DIAGNOSIS; CARNEY COMPLEX; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; GONADOTROPH ADENOMA; GROWTH HORMONE SECRETING ADENOMA; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONFUNCTIONING PITUITARY ADENOMA; NULL CELL ADENOMA; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROLACTINOMA; SYMPTOM; THYROTROPIN SECRETING ADENOMA; TREATMENT RESPONSE;

ACTH-SECRETING PITUITARY ADENOMA; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MALE; PROLACTINOMA;

EID: 66749154751     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000192449     Document Type: Conference Paper

References (58)

1. Asa SL, Ezzat S: The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-849.
2. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-4775.
3. DeLellis RA, Lloyd RA, Heitz PU, Eng C (eds): Pathology and Genetics of Tumours of Endocrine Organs. Geneva, IARC, 2004.
4. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Val-des-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91:3316-3323.
5. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI, Bertagna X, Garcia BN, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A: Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007;92:1891-1896.
6. Villa C, Magri F, Morbini P, Falchetti A, Scagnelli P, Lovati E, Locatelli D, Canevari FR, Necchi V, Gabellieri E, Guabello G, Chiovato L, Solcia E: Silent familial isolated pituitary adenomas: histopathological and clinical case report. Endocr Pathol 2008 [Epub ahead of print].
7. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Peters G, Bolger GB, Chappie JP, Frohman LA, Grossman AB, Korbonits M: The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008;93: 2390-2401.
8. Bevan JS, Burke CW, Esiri MM, Adams CB: Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987;82:29-32.
9. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA: Do the limits of serum prolactin in disconnection hyperprolacti-naemia need re-definition? A study of 226 patients with histologically verified nonfunctioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006;65:524-529.
10. Aylwin SJ, Welch JP, Davey CL, Geddes JF, Wood DF, Besser GM, Grossman AB, Monson JP, Burrin JM: The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab 2001;86:2476-2483.
11. Kontogeorgos G: Null cell pituitary adenomas are gonadotroph adenomas in origin. Pituitary Congress, Stresa, Italy, 2008.
12. Hanson PL, Aylwin SJ, Monson JP, Burrin JM: FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas. Eur J Endocrinol 2005; 152:363-370.
13. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T: A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 2007;61:580-584.
14. Tateno T, Izumiyama H, Doi M, Akashi T, Ohno K, Hirata Y: Defective expression of prohormone convertase 1/3 in silent cortico-troph adenoma. Endocr J 2007;54:777-782.
15. Karavitaki N, Ansorge O, Wass JA: Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 2007;51:1314-1318.
16. Farrell WE, Coll AP, Clayton RN, Harris PE: Corticotroph carcinoma presenting as a silent corticotroph adenoma. Pituitary 2003;6: 41-47.
17. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W: Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultra-structural study. Am J Pathol 1980;98:617-638.
18. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws ER Jr, Young WF Jr: Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 2000; 47:723-729.
19. Bradley KJ, Wass JA, Turner HE: Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf) 2003;58:59-64.
20. Lopez JA, Kleinschmidt-Demasters BB, Sze CI, Woodmansee WW, Lillehei KO: Silent corticotroph adenomas: further clinical and pathological observations. Hum Pathol 2004;35:1137-1147.
21. Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr: Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 2003;53:1076-1084.
22. lino K, Oki Y, Matsushita F, Yamashita M, Hayashi C, Miura K, Nishizawa S, Nakamura H: Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease. Pituitary 2007; 10:35-45.
23. Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, Laws ER Jr, Singer W: A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab 1988;66: 1111-1118.
24. Grossman AB: The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathol 2006;111:76-77.
25. Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D, Abs R: Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 2008 [Epub ahead of print].
26. Ohta S, Nishizawa S, Oki Y, Yokoyama T, Namba H: Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I - immunohistochemical study. Pituitary 2002;5:221-223.
27. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Oyama K, Yamada S, Hirata Y: Differential gene expression in ACTH-secreting and non-functioning pituitary tumors. Eur J Endocrinol 2007; 157: 717-724.
28. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761-767.
29. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S: Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999; 13: 156-166.
30. Musat M, Korbonits M, Kola B, Borboli N, Nanzer AM, Basu S, Grigson J, Jordan S, Gueorguiev M, Morris DG, Coculescu M, Grossman AB: Enhanced protein kinase B/AKT signalling in pituitary tumours. 11th Congress of the European Neuroendocrine Association, Sorrento, Italy, 2004; Abstract 07.3.
31. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL: Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002;109:69-78.
32. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak S, Hanzely Z, Kola B, Korbonits M, Grossman AB: A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 2007;66:348-352.
33. Tziortzioti V, Ruebel KH, Kuroki T, Jin L, Scheithauer BW, Lloyd RV: Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol 2001;12:125-136.
34. Xu B, Sano T, Yoshimoto K, Yamada S: Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 2002;13:341-351.
35. Sano T, Rong QZ, Kagawa N, Yamada S: Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 2004; 32:127-132.
36. Oikonomou E, Barreto DC, Soares B, De Marco L, Buchfelder M, Adams EF: Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. J Neurooncol 2005; 73:205-209.
37. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJ, Cook RJ, Little NS, Clif-ton-Bligh RJ, Robinson BG, McDonald KL: Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 2008; 149:1235-1242.
38. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB: Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 2000; 143:R1-R6.
39. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hed-ley-Whyte ET, Klibanski A: Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2008;93:4119-4125.
40. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, Czirjak S, Hanzely Z, Nagy GM, Goth MI, Grossman AB, Korbonits M: Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006;155:371-379.
41. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007;14:91-102.
42. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ: Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002;87:4238-4244.
43. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC: Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromo-granin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89: 5181-5188.
44. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani G, Cellai I, Ammannati F, Spada A, Serio M, Peri A: Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005;90:6156-6161.
45. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A, Lania A: Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006;13:955-962.
46. Pagotto U, Arzberger T, Ciani E, Lezoualc'h F, Pilon C, Journot L, Spengler D, Stalla GK: Inhibition of Zacl, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology 1999; 140: 987-996.
47. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK: Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phospha-tidylinositol 3-kinase signaling and inducing Zacl expression. Cancer Res 2006;66: 1576-1582.
48. Barz T, Hoffmann A, Panhuysen M, Spengler D: Peroxisome proliferator-activated receptor gamma is a Zac target gene mediating Zac antiproliferation. Cancer Res 2006;66: 11975-11982.
49. Emery MN, Leontiou CA, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB: PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-prolif-erative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf) 2006;65:389-395.
50. Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
51. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
52. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 2008;115:261-262.
53. Kurzen H, Schmitt S, Naher H, Mohler T: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 2003; 14: 515-522.
54. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007;10:81-86.
55. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE: Temozolomide therapy in a man with an aggressive prolac-tin-secreting pituitary neoplasm: morphological findings. Hum Pathol 2007;38:185-189.
56. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE: Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006;105:621-626.
57. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 2006;65: 552-553.
58. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP: Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006; 7:518-520.